RTW Biotech Opportunities invests $275 million in Encoded Therapeutics
RTW Biotech Opportunities Ltd says it is arranging a $275 million financing to advance ETX101 through pivotal development in Dravet syndrome.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.